RxDoctor Payments Data

Caroline Nguyen-Min, MD

Internal Medicine · Orlando, FLNPI 1588950265

Payments from drug & device makers

$701in general payments, 2019–2025

Across 39 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$120
  • Exact Sciences$101
  • Pfizer$67
  • Boehringer Ingelheim$55
  • Takeda Pharmaceuticals U.S.A., Inc.$48
  • Amarin Pharma, Inc.$37
  • plus $273 from 13 others

What the payments were for

  • Food & beverage$67196%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$701 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$123,303
Medicare patients
358
Services billed
1,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$107,534
JardianceEmpagliflozin39$55,909
JanuviaSitagliptin Phosphate34$44,449
EliquisApixaban25$38,857
MounjaroTirzepatide24$29,960
LinzessLinaclotide16$12,747
SynthroidLevothyroxine Sodium70$6,174
SymbicortBudesonide/Formoterol Fumarate11$4,238
Amlodipine Besylate440$3,321
Atorvastatin Calcium455$3,308
Rosuvastatin Calcium232$3,021
Levothyroxine Sodium311$2,880
Losartan Potassium242$2,802
Omeprazole164$2,320
Pantoprazole Sodium137$2,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$120$107,53470 claims
Boehringer IngelheimJardiance$55$55,90939 claims
MerckJanuvia$28$44,44934 claims
PfizerEliquis$67$38,85725 claims
Lilly USA, LLCMounjaro$17$29,96024 claims
AbbVieLinzess, Synthroid$30$18,92186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →